However, since the inhibitory effect of the NADPH oxidase system through activation of PPARα has been observed in studies other than studies using metabolic disorder models [34,35], pemafibrate may have a direct inhibitory effect on the production of ROS via inactivation of the NADPH oxidase system, independent of metabolic disorders, including lipid metabolism. This evidence concerns the gene FMO5 and metabolic disease.